David B. Agus, MD

Professor of Medicine and Biomedical Engineering

Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

Director, USC Center for Applied Molecular Medicine

Image of David B. Agus, MD
Is this your profile? Click to edit

Overview

David B. Agus is a professor of medicine and engineering at the University of Southern California’s Keck School of Medicine and Viterbi School of Engineering. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in new technologies and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and the Global Health Security Consortium. He is also a CBS News contributor. Dr. Agus’ three books “The End of Illness”, “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are all New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital and fellowship at Memorial Sloan-Kettering Cancer Center.

Awards

  • American Cancer Society: Physician Research Award, 1996
     – 2001
  • Sloan-Kettering Institute: Clinical Scholar Award, 1996
  • American Cancer Society: Clinical Oncology Fellowship Award, 1994
  • HealthNetwork Foundation: Excellence Award, 2008
  • Geoffrey Beene Foundation: Rock Stars of Science™, 2009
  • Biotech Humanitarian Award: Selected Judge, 2009
  • USC Association of Trojan Leagues: Outstanding Service Award, 2013
  • American College of Physicians: Fellow, 2016
  • Ellis Island Medal of Honor: Medalist, 2017

Research Funding

  • (PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
    NIH · R01CA180149 · Sep 5, 2013 – Jul 31, 2018 · Role: Principal Investigator
  • UCLA SPORE in Prostate Cancer
    NIH · P50CA092131 · Jul 1, 2001 – Aug 31, 2024 · Role: Co-Principal Investigator

Publications

  • Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007 Apr 01; 13(7):1979-86.. View in PubMed
  • Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81.. View in PubMed
  • Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1208-15.. View in PubMed
  • Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9.. View in PubMed
  • Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7.. View in PubMed
  • Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006 Jan 16; 94(1):85-92.. View in PubMed
  • 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15; 104(12):2701-8.. View in PubMed
  • A perspective on protein profiling of blood. BJU Int. 2005 Sep; 96(4):477-82.. View in PubMed
  • Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63.. View in PubMed
  • Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43.. View in PubMed